RBC Bioscience Corporation (TPEX:6848)

Market Cap	203.07M -20.2%
Revenue (ttm)	201.85M +3.7%
Net Income	19.59M +13.5%
EPS	1.36 +13.6%
Shares Out	12.98M
PE Ratio	11.47
Forward PE	n/a
Dividend	0.30 (2.01%)
Ex-Dividend Date	Oct 2, 2025

Volume	36,342
Average Volume	12,249
Open	15.00
Previous Close	14.95
Day's Range	14.95 - 15.70
52-Week Range	14.30 - 19.05
Beta	0.11
RSI	49.65
Earnings Date	Apr 21, 2026

About RBC Bioscience

RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan. It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 52
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6848

Financial Performance

In 2024, RBC Bioscience's revenue was 205.25 million, an increase of 19.01% compared to the previous year's 172.47 million. Earnings were 21.57 million, an increase of 235.40%.